Trillium Therapeutics Inc. (TRIL)

Oncology Corporate Profile

Stock Performance

6.1500
-0.1000

HQ Location

96 Skyway Avenue
Toronto, Ontario, Canada M9W 4Y9

Company Description

Trillium Therapeutics Inc. is an immuno-oncology company developing innovative therapies for the treatment of cancer. The Company has two premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system.

Website: http://trilliumtherapeutics.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
TTI-621 (SIRPaFc)CD47 inhibitorVarious cancer typesI

Source


http://trilliumtherapeutics.com

Recent News Headlines

Trillium Reports Annual 2016 Financial and Operating Results

3/10/2017 12:00 pm

[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the ...

Trillium Therapeutics Provides Additional Details on ASCO-SITC Conference Presentation on TTI-621

2/24/2017 04:03 pm

[Marketwired] - Trillium Therapeutics Inc. , a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today presented new pharmacology data from its ongoing Phase 1 a/b trial ...

Trillium Therapeutics to Present New Data from TTI-621 Phase 1 Trial

2/15/2017 12:00 pm

[Marketwired] - Trillium Therapeutics Inc. , a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it will present new data from the Phase 1 trial of ...

Trillium Therapeutics to Present at Investor and Scientific Conferences in February

2/7/2017 12:00 pm

[Marketwired] - Trillium Therapeutics Inc. a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the ...

Trillium Therapeutics Outlines Anticipated Activities and Milestones for 2017

2/2/2017 12:00 pm

[Marketwired] - Trillium Therapeutics Inc. , a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today outlined its expected 2017 activities and milestones.

Trillium Therapeutics Doses First Patient With TTI-621 in Phase 1 Solid Tumor Trial

1/31/2017 12:00 pm

[Marketwired] - Trillium Therapeutics Inc. , a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has initiated dosing in its second Phase 1 clinical ...

Trillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies at the American Society of Hematology Annual Meeting

12/3/2016 05:00 pm

[Marketwired] - Trillium Therapeutics Inc. , a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today presented data from an ongoing study with its lead drug candidate, ...

Trillium Therapeutics Announces Conference Call and Webcast on December 5th to Discuss TTI-621 Data Presented at ASH

11/29/2016 12:00 pm

[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it will host a conference call and webcast at 8:30 ...

Trillium reports 3Q loss

11/10/2016 02:00 pm

Trillium reports 3Q loss

11/10/2016 02:00 pm

Trillium Reports Third Quarter 2016 Financial Results and Provides Corporate Update

11/10/2016 12:00 pm

[Marketwired] - Trillium Therapeutics Inc. (TRIL)(TR.TO), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the three and nine months ended September 30, 2016. "We established a well-tolerated dose of TTI-621 in first part of the Phase 1a/1b trial in relapsed or refractory hematologic malignancies and look forward to presenting data at next month's ASH meeting. In November, the Phase 1b dose expansion cohorts in the TTI-621 trial in patients with advanced hematologic malignancies were opened for enrollment.

Trillium Therapeutics Advances TTI-621 into Phase 1b Cohort Expansion Enrollment

11/3/2016 11:37 am

(Trillium Therapeutics) Nov 2, 2016 - Trillium Therapeutics Inc., a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, has advanced its novel investigational drug TTI-621, a SIRPa-IgG1 Fc fusion protein, from dose escalation into Phase 1b cohort expansion enrollment in patients with advanced hematologic malignancies.

Trillium Therapeutics Announces Investor and Scientific Presentation Schedule for Remainder of 2016

11/3/2016 11:00 am

[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is scheduled to present an update on the company's programs and progress ...

Trillium Therapeutics Advances TTI-621 Into Phase 1b Cohort Expansion Enrollment

11/2/2016 11:00 am

[Marketwired] - Trillium Therapeutics Inc. , a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, has advanced its novel investigational drug TTI-621, a SIRPa-IgG1 Fc fusion ...

Trillium Therapeutics Introduces Industry Postdoctoral Fellowship Program

8/31/2016 11:00 am

[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company has established an industry postdoctoral ...

Trillium Therapeutics to Present at Investor and Scientific Conferences in September

8/23/2016 11:00 am

[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on ...

Trillium Therapeutics Approved by FDA to Commence TTI-621 Phase 1 in Solid Tumors and Mycosis Fungoides

8/17/2016 11:19 am

(Stockwatch) Aug 17, 2016 - Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the US Food and Drug Administration (FDA) has provided the company clearance to initiate a Phase 1 clinical trial of its lead drug candidate, TTI-621 (SIRPaFc), in solid tumors and mycosis fungoides.

Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides

8/17/2016 11:00 am

[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the US Food and Drug Administration has provided ...

Trillium reports 2Q loss

8/12/2016 11:05 am